Commentary|Videos|February 3, 2025
Long-Term Transfusion Independence Data for Luspatercept vs ESAs in Lower-Risk MDS
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss long-term transfusion independence data for luspatercept in MDS.
Advertisement
Episodes in this series
Advertisement
Related to this article
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
Ropeginterferon alfa-2b has been approved by Health Canada for the treatment of adult patients with polycythemia vera.
Long-term follow-up from the REVIVE and THRIVE studies showed a low thromboembolic event rate with rusfertide in phlebotomy-dependent polycythemia vera.
Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.
Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.
The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.
Advertisement
Advertisement
Trending on OncLive
1
Frontline Sac-TMT Plus Pembrolizumab Meets PFS End Point in PD-L1–Negative, Nonsquamous NSCLC
2
Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer
3
Dr Cerchione on the FDA Approval of Subcutaneous Isatuximab in Myeloma
4
CAR T-Cell Engineering Produces Early Efficacy Signals in Glioblastoma
5